USAMRIID

First Human Clinical Study to Assess U.S. Department of Defense DNA Vaccine Candidate against Venezuelan Equine Encephalitis Delivered with PharmaJet Precision Delivery Systems.

Retrieved on: 
Thursday, November 16, 2023
Medical Devices, Medical Supplies, Homeland Security, Public Policy, Government, Clinical Trials, Biotechnology, White House, Federal Government, Health, Pharmaceutical, Stratis, ID, Institutional review board, MCDC, VEE, DNA, IRB, Alphavirus, Clinical trial, Mortality, Epidemic, DTRA, FDA, Venezuelan equine encephalitis virus, NHP, USAMRIID, Use, Injection, Unitary state, Infection, Vaccine

The Phase 1 study, sponsored by PharmaJet, aims to identify the optimal dose, vaccination schedule and delivery system most suitable for use in subsequent broader clinical evaluations of the VEE DNA vaccine candidate.

Key Points: 
  • The Phase 1 study, sponsored by PharmaJet, aims to identify the optimal dose, vaccination schedule and delivery system most suitable for use in subsequent broader clinical evaluations of the VEE DNA vaccine candidate.
  • The VEE DNA vaccine candidate is being evaluated as part of a multi-year agreement between PharmaJet and the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA) .
  • The study, in collaboration with USAMRIID, aims to further advance the clinical assessment of the vaccine with the PharmaJet Precision Delivery Systems: Tropis Intradermal (ID) and Stratis Intramuscular (IM).
  • The PharmaJet Precision Delivery Systems are optimized for field use and have also shown immunogenicity levels higher than with needle-syringe.

Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens

Retrieved on: 
Wednesday, October 25, 2023
CRADA, Ageing, Cooperative research and development agreement, Therapy, Maxwell, United States Army Medical Research and Development Command, Biological warfare, U.S. Army Public Health Center, United States Army Medical Research Institute of Infectious Diseases, Development, USAMRIID, McClure, Infection, Peptide, Vaccine

USAMRIID to study antiviral activity of Claromer technology against national priority biodefense threats

Key Points: 
  • Part of the U.S. Army Medical Research and Development Command, USAMRIID is the U.S Army's premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland.
  • "As a military veteran, I'm proud to lead a team that tirelessly seeks to fill critical unmet needs for more effective therapeutics against the worst global pathogens."
  • "Our Claromer technology has the potential to replace almost all antibiotics, antifungals and antivirals - and it may help with healthy aging as well," continued McClure.
  • "Signing this CRADA with USAMRIID, the world's preeminent biodefense research organization, is another validation of Maxwell's Claromer technology's potential as an important, disruptive platform technology."

Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors

Retrieved on: 
Wednesday, October 18, 2023
Storm, Biomedical Advanced Research and Development Authority, Global health, United States Army Nurse Corps, Certification, Civilization, Defense Advanced GPS Receiver, United States Army War College, Medicine, Kosovo Force, Combat support hospital, RN, Commanding officer, Health, Development, American Public University System, Disease, BioBridge Global, RET, University of Kansas, USAMRIID, University, Fort Detrick, National security, Pandemic, United States Army Medical Research and Development Command, ROTC, Infection, Texas Desert Shield-Desert Storm Campaign Medal, BSN, MSN, Scientific Committee on Oceanic Research, Operation New Dawn, 67th Combat Support Hospital (United States), Nursing, Operation, DARPA

Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.

Key Points: 
  • Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
  • This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.
  • "I am pleased to welcome General Holcomb's leadership in national security and patient care to Maxwell's board as we approach human trials next year," said Maxwell Biosciences Chairman and CEO Joshua McClure.
  • "General Holcomb is a highly patient-focused medical professional with decades of deep respect within the global and national security biodefense communities.

Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, Arbovirus, Gold medal, United States Army Medical Research Institute of Infectious Diseases, Private sector, Sabin Vaccine Institute, Gold, USAMRIID, Vaccination, Virology, Public, Rising Star, Infection, Yellow fever, Smallpox, DRS, Viral, Research, CDC, Fever Dream, Division, Finan, United States Department of the Army, Korea Disease Control and Prevention Agency, Lassa fever, Health, Knowledge, Viral encephalitis, Science, R, System, MPH, Immunization, MD

WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.

Key Points: 
  • WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.
  • Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs.
  • Sabin’s Rising Star is awarded to encourage and recognize the next generation of vaccine and immunization leaders.
  • “With his focus on strengthening immunization and health services among some of our most neglected communities, Dr. Nchinjoh exemplifies the spirit behind the Rising Star award,” says Finan.

PharmaJet Announces U.S. Government Award Expansion to Clinically Assess a DNA Vaccine Combined with its Systems

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Stratis, Injection, United States Army Medical Research Institute of Infectious Diseases, DNA, Human, Partnership, Use, Alphavirus, U.S. Department of Defense Strategy for Operating in Cyberspace, USAMRIID, Licensure, Venezuelan equine encephalitis virus, DTRA, ID, Epidemic, Investigational New Drug, PDS, CGMP, Mortality, NHP, Defense Threat Reduction Agency, Encephalitis, IND, Infection, Pharmaceutical industry, Vaccine

The expansion award, worth over $4 million, will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.

Key Points: 
  • The expansion award, worth over $4 million, will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.
  • Venezuelan Equine Encephalitis Virus is an alphavirus that causes encephalitis and potential mortality in infected humans and equines.
  • It is listed as a potential biothreat agent with no approved human vaccine or therapeutic currently available.
  • PharmaJet is working with a contract manufacturer to produce the cGMP VEEV plasmid DNA vaccine and is preparing the Investigational New Drug (IND) application.

Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.

Retrieved on: 
Thursday, February 2, 2023
Research, Food, USAMRIID, Infection, Plasma protein binding, United States Army Medical Research Institute of Infectious Diseases, Center for Global Infectious Disease Research, Tonix Pharmaceuticals, Peginterferon alfa-2a, Viral hepatitis, Maraviroc, Immune system, HIV, Jeju Free International City Development Center, Drug development, Tocilizumab, Viral load, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Severe acute respiratory syndrome coronavirus 2, Tissue, CCR5, RDC, Vaccine, Paul Healion

CHATHAM, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets. Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes. Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2.

Key Points: 
  • Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action.
  • Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes.
  • Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2.
  • On behalf of the talented scientific team that I direct at our 48,000 square-foot cutting-edge infectious disease research facility in Frederick, Md., I am pleased to add this technology to the therapeutic development programs underway.”

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development

Retrieved on: 
Monday, July 25, 2022
Nuclear physics, SL, Psychiatry, Monkeypox, Infection, CNS, Company, Security (finance), Smallpox, Running, Translational research, Prader–Willi syndrome, Research, U.S. Securities and Exchange Commission, Cancer, University, Cocaine, Pain, Neurology, IND, Long COVID, GLOBE, Fibromyalgia, Industry, SEC, Government, Disease, RDC, Hydrogen chloride, Failure, COVID-19, Pharmacy, Achievement, Central nervous system, Nuclear pharmacy, Autoimmunity, FDA, Nebraska Medicine, CD154, University of Nebraska Medical Center, Nasdaq, Therapy, Annual report, Risk, Vaccine, Bavari, Private Securities Litigation Reform Act, USAMRIID, Leadership, United States Army Research Institute of Environmental Medicine, Investigational New Drug, Education Development Center, Degenerative disease, Pharmaceutical industry, Tonix Pharmaceuticals, Immunology

CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development.

Key Points: 
  • CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development.
  • and, as part of his role, will oversee scientific development at Tonixs Infectious Disease R&D Center located there.
  • We are delighted that Dr. Bavari has joined our team to lead our infectious disease research and development efforts, said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals.
  • I am excited to join Tonix and to lead the Company's efforts in infectious disease research and development programs, including vaccines in development for monkeypox, smallpox and COVID-19, said Dr. Bavari.

PharmaJet Presents Latest Research Showing Benefits of Needle-free at mRNA-Based Therapeutics Summit

Retrieved on: 
Tuesday, July 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Infectious Diseases, Stratis, N/S, Research, Public health, LNP, University, Rabies, USAMRIID, Method, LinkedIn, RNA transfection, WHO, Infection, Injection, Safety, DVM, Therapy, Review, System, Lancet, Rabbit, United States Army Medical Research Institute of Infectious Diseases, Certification, Use, Sue VandeWoude, Smallpox, Vaccination, Nucleic acid, COVID-19, ID, PQS, CE marking, Veni, vidi, vici, Doctor of Philosophy, IM, U.S. FDA, Vaccine, TROPI

PharmaJet , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022.

Key Points: 
  • PharmaJet , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022.
  • The presentation, entitled Advances in mRNA vaccines and therapeutics delivery with PharmaJet Needle-free Injection Systems, will be presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet.
  • PharmaJet Needle-free Injection Systems (NFIS) are increasingly being incorporated into preclinical and clinical studies across multiple nucleic acid vaccine and therapeutic development programs.
  • This presentationwill highlight several partner studies that show the benefits of the PharmaJet NFIS including improved immunogenicity, dose-reduction, lower cost, and better patient and healthcare worker experience.

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Retrieved on: 
Thursday, April 28, 2022
Mpro, Solution, Program, USAMRIID, Vaccine, CEO, Biotechnology, Percussion section, Fujifilm, Infection, Health, MD, Protease, Multimedia, Research, View, Digital imaging, United States Department of Defense, Hand, Risk, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Molnupiravir, Favipiravir

The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.

Key Points: 
  • The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.
  • Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone.
  • We are working with FUJIFILM Toyama to benefit from their decades of experience in oral antivirals."
  • For more information, please visit: holdings.fujifilm.com
    Healion Bio, Inc., Frederick, MD, is a biotechnology development company developing the next generation of antiviral compounds.

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Retrieved on: 
Thursday, April 28, 2022
Mpro, Solution, Program, USAMRIID, Vaccine, CEO, Biotechnology, Percussion section, Fujifilm, Infection, Health, MD, Protease, Research, Digital imaging, United States Department of Defense, Hand, Risk, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Molnupiravir, Favipiravir

The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.

Key Points: 
  • The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.
  • Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone.
  • We are working with FUJIFILM Toyama to benefit from their decades of experience in oral antivirals."
  • For more information, please visit: holdings.fujifilm.com
    Healion Bio, Inc., Frederick, MD, is a biotechnology development company developing the next generation of antiviral compounds.